Nautilus Biotechnology Cuts Q4 Expenses 23% to $15.4M, Prepares Voyager Launch
Nautilus Biotechnology reduced Q4 operating expenses by 23% to $15.4 million and narrowed net loss to $13.8 million, ending 2025 with $156.1 million in cash and investments, funding operations into 2027. The company launched its Iterative Mapping Early Access Program in January and unveiled its Voyager platform ahead of a late-2026 commercial launch.
1. Financial Performance
For the fourth quarter of 2025, Nautilus Biotechnology reported operating expenses of $15.4 million, a 23% decline from $20.0 million in the prior-year period. Net loss narrowed to $13.8 million from $17.6 million, and year-end cash, cash equivalents and investments totaled $156.1 million, supporting operations through 2027.
2. Business Developments
During Q4, the company processed and analyzed Tau proteoform samples to advance platform validation and scientific publications, presented data at the World HUPO conference, and initiated its Iterative Mapping Early Access Program for Tau proteoforms in January. Nautilus also unveiled its Voyager platform at the US HUPO conference and began a Parkinson’s assay collaboration with The Michael J. Fox Foundation and Weill Cornell Medicine–Qatar.
3. Outlook and Runway
Nautilus expects no material revenue from Early Access Program engagements in 2026 and forecasts a 15–20% year-over-year increase in operating expenses as it scales development. With $156.1 million in cash and investments, the company anticipates funding operations and advancing toward full commercial availability of the Voyager platform by late 2026.